Dwight List Mckee
Physician at Mesa Dr, Aptos, CA
License number
Colorado 22213
Issued Date
Feb 13, 1979
Renew Date
May 31, 1989
Expiration Date
May 31, 1989
Type
Physician
Address
Address
7321 Mesa Dr, Aptos, CA 95003
Personal information
See more information about Dwight List Mckee at radaris.comName
Address
Phone
2290 Brentwood Ct, Palo Alto, CA 94303
290 Dry Creek Rd, Aptos, CA 95003
290 Dry Creek Rd, Aptos, CA 95003
530 Sumner Ave, Aptos, CA 95003
1715 Bonaire Cir, Stockton, CA 95210
Professional information
See more information about Dwight List Mckee at trustoria.com
Product And Method For Oral Administration Of Nutraceuticals
Product And Method For Oral Administration Of Nutraceuticals
US Patent:
7632532, Dec 15, 2009
Filed:
Dec 9, 2005
Appl. No.:
11/298724
Inventors:
Dwight McKee - Aptos CA, US
Amanda Karwic - Elverson PA, US
Amanda Karwic - Elverson PA, US
Assignee:
Eurak, LLC - Batesville AR
International Classification:
A23L 1/236
US Classification:
426548, 426 72, 426 73, 426660
Abstract:
A delivery system for nutraceuticals uses a low caloric chocolate base for containing one or more nutraceuticals, either blended with the chocolate itself, or added as a liquid or crème filling. The chocolate has a relatively high level of oligomeric proanthocyanidins, and preferably further includes a phytosterol and DHA, as well as being sweetened with a sweetener blend containing tagatose and a secondary low caloric, high intensity sweetener, preferably Lo Han Guo extract. Using the inventive system, delivery of nutraceuticals in unit dosage form is facilitated, as the selected dose is carried within individual chocolate product pieces that taste substantially the same as conventional chocolate, though with few calories from carbohydrates, or effects on insulin response encountered with typical chocolate formulations.
Composition And Method For Treating Upper Abdominal Pain And Cramping
Composition And Method For Treating Upper Abdominal Pain And Cramping
US Patent:
2004024, Dec 9, 2004
Filed:
May 19, 2004
Appl. No.:
10/849376
Inventors:
Dwight Mckee - Aptos CA, US
Timothy Nolan - Batesville AR, US
Timothy Nolan - Batesville AR, US
Assignee:
Pro-Health, Inc. - Batesville AR
International Classification:
A61K035/78, A61K031/715
US Classification:
424/744000, 514/561000, 514/054000, 514/563000
Abstract:
A composition for relieving the symptoms of upper intestinal tract discomfort contains aloe vera extract including acemannan, L-glutamine and L-glycine.
Oral Composition For The Treatment And Prevention Of Bone Loss
Oral Composition For The Treatment And Prevention Of Bone Loss
US Patent:
2004012, Jun 24, 2004
Filed:
Dec 20, 2002
Appl. No.:
10/325683
Inventors:
Dwight McKee - Aptos CA, US
International Classification:
A61K035/78, A61K033/06, A61K033/26, A61K031/714, A61K031/7076
US Classification:
424/646000, 424/682000, 424/757000, 514/052000, 514/350000, 514/089000, 514/046000, 514/251000
Abstract:
The invention is a composition and method for treating osteoporosis, bone loss and/or periodontal demineralization involving the oral administration of a formulation containing vanadium and ipriflavone which support an increase in bone mass, a homocysteine inhibitor/reducer to inhibit the counteracting effects of homocysteine on bone rebuilding, and an absorbable calcium salt to provide a ready source of material for bone rebuilding.
Gaba Substrate And The Use Thereof For Treating Cognitive And Emotional Disorders
Gaba Substrate And The Use Thereof For Treating Cognitive And Emotional Disorders
US Patent:
2002004, Apr 25, 2002
Filed:
Apr 12, 2001
Appl. No.:
09/834173
Inventors:
William Evans - Batesville AR, US
Dwight McKee - Aptos CA, US
Dwight McKee - Aptos CA, US
International Classification:
A61K035/78, A61K033/24, A61K031/19
US Classification:
424/752000, 424/617000, 514/557000
Abstract:
The invention is a composition and method for treating the symptoms associated with cognitive and emotional conditions such as attention deficit disorder (ADD), attention deficit/hyper activity disorder (AD/HD), Tourette's Syndrome, some forms of autism, and other physiological conditions. The method involves administration of a formulation containing a GABA substrate composed of at least one alkali metal or alkaline earth metal salt of n-butyric acid, preferably, a mixture of calcium and magnesium butyrate, which crosses the blood brain barrier and transform into GABA, an inhibiting neurotransmitter in the brain.